Together, these findings suggest that a combination of different ICIs has marginal efficacy in MSS CRC but, most importantly, it underlies the lack of clear biomarkers, except for POLE/POLD1 mutation, that could help to select MSS tumor subtypes that would be prone to respond to ICIs. Here, POLE is linked to colorectal carcinoma.